Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.08
+1.3%
$3.24
$3.96
$12.00
$5.52M1.557,305 shs3,223 shs
CohBar, Inc. stock logo
CWBR
CohBar
$0.41
$0.41
$0.00
$1.01
$1.19M1.394,364 shsN/A
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%0.00%0.00%0.00%-18.52%
CohBar, Inc. stock logo
CWBR
CohBar
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.08
+1.3%
$3.24
$3.96
$12.00
$5.52M1.557,305 shs3,223 shs
CohBar, Inc. stock logo
CWBR
CohBar
$0.41
$0.41
$0.00
$1.01
$1.19M1.394,364 shsN/A
The 10 Best AI Stocks to Own in 2026 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%0.00%0.00%0.00%-18.52%
CohBar, Inc. stock logo
CWBR
CohBar
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
CohBar, Inc. stock logo
CWBR
CohBar
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.33N/AN/A$14.99 per share0.21
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/A$5.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/AN/A-760.32%-83.45%-45.76%N/A
CohBar, Inc. stock logo
CWBR
CohBar
-$12.18MN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
CohBar, Inc. stock logo
CWBR
CohBar
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
CohBar, Inc. stock logo
CWBR
CohBar
2.47%

Insider Ownership

CompanyInsider Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.10%
CohBar, Inc. stock logo
CWBR
CohBar
6.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
CohBar, Inc. stock logo
CWBR
CohBar
102.91 millionN/ANot Optionable

Recent News About These Companies

MOLY:CA Greenland Resources Inc.
CohBar, Inc. (CWBR)
CohBar Inc CWBR
Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

CohBar stock logo

CohBar NASDAQ:CWBR

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.